Literature DB >> 25184687

The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis.

Phillip L Molyneaux1, Michael J Cox, Saffron A G Willis-Owen, Patrick Mallia, Kirsty E Russell, Anne-Marie Russell, Elissa Murphy, Sebastian L Johnston, David A Schwartz, Athol U Wells, William O C Cookson, Toby M Maher, Miriam F Moffatt.   

Abstract

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause that leads to respiratory failure and death within 5 years of diagnosis. Overt respiratory infection and immunosuppression carry a high morbidity and mortality, and polymorphisms in genes related to epithelial integrity and host defense predispose to IPF.
OBJECTIVES: To investigate the role of bacteria in the pathogenesis and progression of IPF.
METHODS: We prospectively enrolled patients diagnosed with IPF according to international criteria together with healthy smokers, nonsmokers, and subjects with moderate chronic obstructive pulmonary disease as control subjects. Subjects underwent bronchoalveolar lavage (BAL), from which genomic DNA was isolated. The V3-V5 region of the bacterial 16S rRNA gene was amplified, allowing quantification of bacterial load and identification of communities by 16S rRNA quantitative polymerase chain reaction and pyrosequencing.
MEASUREMENTS AND MAIN RESULTS: Sixty-five patients with IPF had double the burden of bacteria in BAL fluid compared with 44 control subjects. Baseline bacterial burden predicted the rate of decline in lung volume and risk of death and associated independently with the rs35705950 polymorphism of the MUC5B mucin gene, a proven host susceptibility factor for IPF. Sequencing yielded 912,883 high-quality reads from all subjects. We identified Haemophilus, Streptococcus, Neisseria, and Veillonella spp. to be more abundant in cases than control subjects. Regression analyses indicated that these specific operational taxonomic units as well as bacterial burden associated independently with IPF.
CONCLUSIONS: IPF is characterized by an increased bacterial burden in BAL that predicts decline in lung function and death. Trials of antimicrobial therapy are needed to determine if microbial burden is pathogenic in the disease.

Entities:  

Keywords:  Muc5b; bacteria; idiopathic pulmonary fibrosis; microbiome

Mesh:

Substances:

Year:  2014        PMID: 25184687      PMCID: PMC4299577          DOI: 10.1164/rccm.201403-0541OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   30.528


  39 in total

1.  Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.

Authors:  J W Song; S-B Hong; C-M Lim; Y Koh; D S Kim
Journal:  Eur Respir J       Date:  2010-07-01       Impact factor: 16.671

Review 2.  Is idiopathic pulmonary fibrosis an environmental disease?

Authors:  Varsha S Taskar; David B Coultas
Journal:  Proc Am Thorac Soc       Date:  2006-06

3.  A persistent and diverse airway microbiota present during chronic obstructive pulmonary disease exacerbations.

Authors:  Yvonne J Huang; Eugenia Kim; Michael J Cox; Eoin L Brodie; Ron Brown; Jeanine P Wiener-Kronish; Susan V Lynch
Journal:  OMICS       Date:  2010-02

Review 4.  Idiopathic pulmonary fibrosis.

Authors:  Talmadge E King; Annie Pardo; Moisés Selman
Journal:  Lancet       Date:  2011-06-28       Impact factor: 79.321

5.  Viral infection in acute exacerbation of idiopathic pulmonary fibrosis.

Authors:  Sharon Chao Wootton; Dong Soon Kim; Yasuhiro Kondoh; Eunice Chen; Joyce S Lee; Jin Woo Song; Jin Won Huh; Hiroyuki Taniguchi; Charles Chiu; Homer Boushey; Lisa H Lancaster; Paul J Wolters; Joseph DeRisi; Don Ganem; Harold R Collard
Journal:  Am J Respir Crit Care Med       Date:  2011-02-25       Impact factor: 21.405

Review 6.  Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?

Authors:  T M Maher; A U Wells; G J Laurent
Journal:  Eur Respir J       Date:  2007-11       Impact factor: 16.671

7.  Treating idiopathic pulmonary fibrosis with the addition of co-trimoxazole: a randomised controlled trial.

Authors:  Ludmila Shulgina; Anthony P Cahn; Edwin R Chilvers; Helen Parfrey; Allan B Clark; Edward C F Wilson; Orion P Twentyman; Anthony G Davison; John J Curtin; Michael B Crawford; Andrew M Wilson
Journal:  Thorax       Date:  2012-11-10       Impact factor: 9.139

8.  Disordered microbial communities in the upper respiratory tract of cigarette smokers.

Authors:  Emily S Charlson; Jun Chen; Rebecca Custers-Allen; Kyle Bittinger; Hongzhe Li; Rohini Sinha; Jennifer Hwang; Frederic D Bushman; Ronald G Collman
Journal:  PLoS One       Date:  2010-12-20       Impact factor: 3.240

9.  Improved detection of bifidobacteria with optimised 16S rRNA-gene based pyrosequencing.

Authors:  Kathleen Sim; Michael J Cox; Harm Wopereis; Rocio Martin; Jan Knol; Ming-Shi Li; William O C M Cookson; Miriam F Moffatt; J Simon Kroll
Journal:  PLoS One       Date:  2012-03-28       Impact factor: 3.240

10.  UniFrac--an online tool for comparing microbial community diversity in a phylogenetic context.

Authors:  Catherine Lozupone; Micah Hamady; Rob Knight
Journal:  BMC Bioinformatics       Date:  2006-08-07       Impact factor: 3.169

View more
  180 in total

Review 1.  The Microbiome and the Respiratory Tract.

Authors:  Robert P Dickson; John R Erb-Downward; Fernando J Martinez; Gary B Huffnagle
Journal:  Annu Rev Physiol       Date:  2015-11-02       Impact factor: 19.318

2.  Aerobic Glycolysis and the Warburg Effect. An Unexplored Realm in the Search for Fibrosis Therapies?

Authors:  Toby M Maher
Journal:  Am J Respir Crit Care Med       Date:  2015-12-15       Impact factor: 21.405

3.  Gut Microbiota Predict Pulmonary Infiltrates after Allogeneic Hematopoietic Cell Transplantation.

Authors:  Bianca Harris; Sejal M Morjaria; Eric R Littmann; Alexander I Geyer; Diane E Stover; Juliet N Barker; Sergio A Giralt; Ying Taur; Eric G Pamer
Journal:  Am J Respir Crit Care Med       Date:  2016-08-15       Impact factor: 21.405

Review 4.  Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways.

Authors:  Christopher M Evans; Tasha E Fingerlin; Marvin I Schwarz; David Lynch; Jonathan Kurche; Laura Warg; Ivana V Yang; David A Schwartz
Journal:  Physiol Rev       Date:  2016-10       Impact factor: 37.312

5.  Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.

Authors:  Yong Huang; Shwu-Fan Ma; Milena S Espindola; Rekha Vij; Justin M Oldham; Gary B Huffnagle; John R Erb-Downward; Kevin R Flaherty; Beth B Moore; Eric S White; Tong Zhou; Jianrong Li; Yves A Lussier; MeiLan K Han; Naftali Kaminski; Joe G N Garcia; Cory M Hogaboam; Fernando J Martinez; Imre Noth
Journal:  Am J Respir Crit Care Med       Date:  2017-07-15       Impact factor: 21.405

Review 6.  Lungs, microbes and the developing neonate.

Authors:  Barbara B Warner; Aaron Hamvas
Journal:  Neonatology       Date:  2015-06-05       Impact factor: 4.035

7.  Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in idiopathic pulmonary fibrosis.

Authors:  L Ten Klooster; C H M van Moorsel; J M Kwakkel-van Erp; H van Velzen-Blad; J C Grutters
Journal:  Clin Exp Immunol       Date:  2015-06-08       Impact factor: 4.330

Review 8.  The respiratory microbiome in idiopathic pulmonary fibrosis.

Authors:  Richard J Hewitt; Philip L Molyneaux
Journal:  Ann Transl Med       Date:  2017-06

9.  A first glimpse at the early origins of idiopathic pulmonary fibrosis.

Authors:  Oliver Eickelberg; Gary M Hunninghake
Journal:  Am J Respir Crit Care Med       Date:  2015-02-15       Impact factor: 21.405

10.  BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis.

Authors:  Antje Prasse; Harald Binder; Jonas C Schupp; Gian Kayser; Elena Bargagli; Benedikt Jaeger; Moritz Hess; Susanne Rittinghausen; Louis Vuga; Heather Lynn; Shelia Violette; Birgit Jung; Karsten Quast; Bart Vanaudenaerde; Yan Xu; Jens M Hohlfeld; Norbert Krug; Jose D Herazo-Maya; Paola Rottoli; Wim A Wuyts; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.